重组人血小板生成素联合地塞米松治疗原发免疫性血小板减少症的疗效探讨

Investigation of curative effect by recombinant human thrombopoietin combined with dexamethasone in the treatment of primary immune thrombocytopenia

目的探讨重组人血小板生成素联合地塞米松治疗原发免疫性血小板减少症的临床疗效。方法 64例原发免疫性血小板减少症患者,将其随机分成对照组和观察组,每组32例。对照组患者使用地塞米松治疗,观察组患者使用重组人血小板生成素联合地塞米松治疗。比较两组治疗效果。结果治疗后,观察组血小板计数为(132.8±65.6)×10~9/L,高于对照组的(76.8±68.5)×10~9/L,差异有统计学意义(P<0.05);观察组治疗总有效率为84.4%,高于对照组的62.5%,差异具有统计学意义(P<0.05)。观察组不良反应发生率为21.9%,对照组为15.6%,比较差异无统计学意义(P>0.05)。结论重组人血小板生成素联合地塞米松治疗原发免疫性血小板减少症疗效显著,无明显副作用,可在临床推广用。

Objective To investigate clinical effect by recombinant human thrombopoietin combined with dexamethasone in the treatment of primary immune thrombocytopenia. Methods A total of 64 patients with primary immune thrombocytopenia were randomly divided into control group and observation group, with 32 cases in each group. The control group received dexamethasone for treatment, and the observation group received recombinant human thrombopoietin combined with dexamethasone for treatment. Curative effects were compared between the two groups. Results After treatment, the observation group had higher blood platelet count as（132.8±65.6）×10~9/L than（76.8±68.5）×10~9/L in the control group, and their difference had statistical significance（P〈0.05）. The observation group had higher total effective rate in treatment as 84.4% than 62.5% in the control group, and the difference had statistical significance（P〈0.05）. The observation group had incidence of adverse reactions as 21.9%, which was 15.6% in the control group, and the difference had no statistical significance（P〉0.05）. Conclusion Combination of recombinant human thrombopoietin and dexamethasone shows excellent curative effect in treating primary immune thrombocytopenia, without obvious adverse reactions. This method is worth clinical promotion and application.